NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
RMTI
Rockwell Medical, Inc.
RMTI has a slight edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RMTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
RMTI's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RMTI PE Valuation
RMTI has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RMTI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Stable | |
| Limited | |
| High |
RMTI has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RMTI on earnings quality, reporting a profit while its opponent remains loss making.
RMTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.43 | +$0.17 |
| Q2 2026 | -$1.34 | -$0.64 |
| Q1 2026 | -$1.50 | -$1.40 |
| Q4 2025 | -$1.50 | -$1.20 |
| Q3 2025 | -$1.60 | -$1.16 |
| Q2 2025 | -$0.70 | +$0.84 |
| Q1 2025 | -$0.10 | +$3.34 |
| Q4 2024 | -$0.30 | +$3.54 |
RMTI is still losing money, but far less than before: $1.43 per share over the past year, against $61.60 at its worst in late 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over RMTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RMTI on profitability, with a higher operating margin.
RMTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.1M | +20% |
| Q2 2026 | $17.8M | +11% |
| Q1 2026 | $17.3M | -8.3% |
| Q4 2025 | $18.3M | -26% |
| Q3 2025 | $15.9M | -44% |
| Q2 2025 | $16.1M | -38% |
| Q1 2025 | $18.9M | -17% |
| Q4 2024 | $24.7M | +12% |
RMTI's revenue is recovering but still below its 2024 peak: $19M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -1.7 points |
| Q2 2026 | -6% | +2.4 points |
| Q1 2026 | -8.5% | -1.3 points |
| Q4 2025 | -2.2% | -0.1 points |
| Q3 2025 | -10% | -17 points |
| Q2 2025 | -8.4% | -10 points |
| Q1 2025 | -7.2% | -1.4 points |
| Q4 2024 | -2.1% | +0.4 points |
RMTI's operating margin was −12% last quarter, down 1.7 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
RMTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.2M | -$712K |
| Q2 2026 | $1.5M | -13% |
| Q1 2026 | -$592K | +$3M |
| Q4 2025 | $2.2M | +369% |
| Q2 2025 | $1.7M | +17% |
| Q1 2025 | -$3.6M | -$1.2M |
| Q4 2024 | $470K | +$513K |
| Q2 2024 | $1.4M | +$3.2M |
RMTI has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RMTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RMTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +13.4K shares |
| 1 year | +10% | +369K shares |
| 3 years | +115% | +2.1M shares |
| 5 years | +367% | +3.1M shares |
| Available history | +617% | +3.4M shares |
RMTI has 4M diluted shares, up 10% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RMTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -4.3x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -2.6x | Net Cash |
| Q3 2024 | -1.4x | Net Cash |
RMTI has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RMTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.4 | Neutral |
| Stochastic | 34.5 | Neutral |
RMTI's weekly RSI is 46 (neutral) and its Stochastic is 34 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RMTI PE vs Healthcare Sector
RMTI has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RMTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.68 | 3.9% below |
| 20 week MA | $7.37 | 0.1% above |
| 50 week MA | $8.25 | 11% below |
| 100 week MA | $10.8 | 32% below |
| 200 week MA | $17.0 | 57% below |
RMTI's trend is mixed: it's above one of its five weekly moving averages, and 57% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
RMTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $258.5 | $111.1 | -57% |
| 2021 | $111.1 | $44.0 | -60% |
| 2022 | $44.0 | $9.70 | -78% |
| 2023 | $9.70 | $18.9 | +95% |
| 2024 | $18.9 | $21.4 | +13% |
| 2025 | $21.4 | $8.65 | -60% |
| 2026 YTD | $8.65 | $7.38 | -15% |
RMTI has the edge over NVO on returns for 2026, with the stronger performance.